Zoetis Inc. announced on June 2, 2025, the launch of AI Masses, the newest artificial intelligence (AI) powered analysis technology for its Vetscan Imagyst® analyzer. This new capability delivers fast and accurate in-clinic screening of common lymph node and skin/subcutaneous lesions.
AI Masses detects potentially neoplastic cells in minutes, supporting veterinary professionals in making informed decisions and streamlining diagnoses. This addition makes Vetscan Imagyst the world's most capable veterinary AI analyzer with a total of seven unique testing applications.
Abhay Nayak, President, Global Diagnostics at Zoetis, highlighted that this innovation empowers veterinary teams with valuable insights into potentially cancerous cells, reducing waiting times and alleviating stress for pet owners. The new capability will be available on all Vetscan Imagyst analyzers in North America immediately.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.